BACKGROUND: Catheter-related bloodstream infections remain costly with no simple prevention. We report preliminary results of a phase I trial of ethanol-lock administration to prevent mediport catheter-related bloodstream infections in children. METHODS: Twelve patients receiving intravenous antibody treatments for neuroblastoma were enrolled. On 4 days of each 5-day antibody cycle, 70% ethanol was administered instead of heparin to dwell in each patient's mediport overnight. We used clinical monitoring/questionnaires to assess symptoms and measured blood ethanol levels and liver functions. Patients were tracked for positive blood cultures. Time to infection for ethanol-lock-treated patients was compared with historical controls. RESULTS: We administered 123 ethanol-locks. No adverse symptoms attributable to ethanol occurred; one patient's urticaria worsened. Blood ethanol levels averaged 11 mg/dL. The study was voluntarily suspended after 3 patients' catheters became occluded, 1 of which fractured. A positive blood culture occurred in 1 (8%) of 12 patients, but suspension of the study precluded statistical power to detect impact on time to infection. CONCLUSIONS: Although children with mediport catheters exhibited nontoxic blood ethanol levels and a low rate of bloodstream infections following prophylactic ethanol-lock use, there was a high incidence of catheter occlusion. Adjustments are necessary before adopting ethanol-locks for routine prophylaxis against catheter infections in children.
BACKGROUND: Catheter-related bloodstream infections remain costly with no simple prevention. We report preliminary results of a phase I trial of ethanol-lock administration to prevent mediport catheter-related bloodstream infections in children. METHODS: Twelve patients receiving intravenous antibody treatments for neuroblastoma were enrolled. On 4 days of each 5-day antibody cycle, 70% ethanol was administered instead of heparin to dwell in each patient's mediport overnight. We used clinical monitoring/questionnaires to assess symptoms and measured blood ethanol levels and liver functions. Patients were tracked for positive blood cultures. Time to infection for ethanol-lock-treated patients was compared with historical controls. RESULTS: We administered 123 ethanol-locks. No adverse symptoms attributable to ethanol occurred; one patient's urticaria worsened. Blood ethanol levels averaged 11 mg/dL. The study was voluntarily suspended after 3 patients' catheters became occluded, 1 of which fractured. A positive blood culture occurred in 1 (8%) of 12 patients, but suspension of the study precluded statistical power to detect impact on time to infection. CONCLUSIONS: Although children with mediport catheters exhibited nontoxic blood ethanol levels and a low rate of bloodstream infections following prophylactic ethanol-lock use, there was a high incidence of catheter occlusion. Adjustments are necessary before adopting ethanol-locks for routine prophylaxis against catheter infections in children.
Authors: Christopher J Crnich; Jeremy A Halfmann; Wendy C Crone; Dennis G Maki Journal: Infect Control Hosp Epidemiol Date: 2005-08 Impact factor: 3.254
Authors: N K Cheung; B H Kushner; I Y Cheung; K Kramer; A Canete; W Gerald; M A Bonilla; R Finn; S J Yeh; S M Larson Journal: J Clin Oncol Date: 1998-09 Impact factor: 44.544
Authors: S L Werlin; T Lausten; S Jessen; L Toy; A Norton; L Dallman; J Bender; L Sabilan; D Rutkowski Journal: JPEN J Parenter Enteral Nutr Date: 1995 Sep-Oct Impact factor: 4.016
Authors: Melissa A Shenep; Mary R Tanner; Yilun Sun; Tina Culley; Randall T Hayden; Patricia M Flynn; Li Tang; Joshua Wolf Journal: JPEN J Parenter Enteral Nutr Date: 2016-01-07 Impact factor: 4.016
Authors: Riad Rahhal; Maisam A Abu-El-Haija; Lin Fei; Dawn Ebach; Sarah Orkin; Elizabeth Kiscaden; Conrad R Cole Journal: JPEN J Parenter Enteral Nutr Date: 2017-12-19 Impact factor: 4.016
Authors: Gernot Schilcher; Axel Schlagenhauf; Daniel Schneditz; Hubert Scharnagl; Werner Ribitsch; Robert Krause; Alexander R Rosenkranz; Tatjana Stojakovic; Joerg H Horina Journal: PLoS One Date: 2013-12-31 Impact factor: 3.240
Authors: Jennifer K Broom; Rathika Krishnasamy; Carmel M Hawley; E Geoffrey Playford; David W Johnson Journal: BMC Nephrol Date: 2012-11-02 Impact factor: 2.388
Authors: Joshua Wolf; Li Tang; Jeffrey E Rubnitz; Rachel C Brennan; David R Shook; Dennis C Stokes; Paul Monagle; Nigel Curtis; Leon J Worth; Kim Allison; Yilun Sun; Patricia M Flynn Journal: PLoS One Date: 2015-08-31 Impact factor: 3.240
Authors: Cesar Bustos; Aitziber Aguinaga; Francisco Carmona-Torre; Jose Luis Del Pozo Journal: Infect Drug Resist Date: 2014-02-18 Impact factor: 4.003